The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 318 participants.

Also called NCT01364220

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 318 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01364220
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01364220. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Acronym
EUREKA
Condition
Stroke
Intervention (Drug)
Rosuvastatin
Intervention (Other)
Placebo tablet
Lead sponsor
Severance Hospital (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01364220
Content hash
50a9b07615cb0215dba793db61dadec8865814bced952b3850eaf7b5088fa7bd